{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "TLRY",
  "name": "Tilray Brands, Inc.",
  "url": "https://orbyd.app/dossiers/TLRY/",
  "json_url": "https://orbyd.app/dossiers/TLRY.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Reform binary spent without resolving: the DEA hearing closed 2026-07-15 with only a 2026-08-17 briefing deadline and no ALJ timeline, so Schedule III is now an open-ended administrative process. TLRY printed a fresh 52-week low of $4.20 on 2026-07-08 during the hearing itself and sits below the 200-day into Q4 earnings 2026-07-28. Broken structure, no dated catalyst.",
  "invalidation_trigger": "A daily close below $4.20 breaks the 2026-07-08 52-week low and confirms the downtrend; the constructive case only re-opens on a daily close above $5.00, and separately if the Q4 print on 2026-07-28 misses the reaffirmed $62–72M FY adjusted-EBITDA band.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-06-25",
  "invalidation_fired": true,
  "themes": [
    "cannabis-reclassification"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "DEA hearing CONCLUDED 2026-07-15. Post-hearing briefs due 2026-08-17 (50-page cap); ALJ Derek Julius recommendation on NO announced timeline; final decision rests with the DEA Administrator and is litigable. The dated reform catalyst no longer exists — do not carry 2026-06-29 forward.",
    "New 52-week low $4.20 set 2026-07-08 — the old $4.50 shelf and the prior $3.93 reference are both void. Structure requires a daily close above ~$5.80–6.00 to reclaim the 200-day before any momentum entry.",
    "Canonical cannabis-reform value trap: round-tripped ~$5 → ~$23 → ~$4. Never average down; re-entry only on a fresh higher low plus a reclaim.",
    "TD Cowen cut PT to $5 from $7 on 2026-07-14 while maintaining Buy. Consensus PT ~$6.33 — both above spot, which is normal for a broken-tape name and not a signal.",
    "BrewDog makes TLRY ~$1.2B annualized; cannabis is only ~31% of revenue, structurally diluting reform beta versus purer US-exposed peers.",
    "Germany/international medical cannabis (+70% YoY in Q3 FY2026) is the only genuinely accelerating leg and is independent of US federal policy. Panama medical launch 2026-07-09 extends it.",
    "Hemp recriminalization effective ~2026-11-12 (Continuing Appropriations Act, signed 2025-11-12); ~95% of hemp-cannabinoid products swept out per U.S. Hemp Roundtable. H.R. 7024 deferral to 2028 would be a sector-wide negative — track it.",
    "Dilution active: Lyphe Group funded with ~1.6M new shares in early June 2026 plus a debt-for-equity retirement of $6M of 2027 converts."
  ],
  "body_markdown": "## Current Thesis\nThe event that justified owning TLRY has come and gone without producing an event. The DEA's expedited rescheduling hearing opened 2026-06-29 and closed 2026-07-15, and Chief ALJ Derek Julius adjourned it not with a recommendation but with a briefing schedule: post-hearing briefs of up to 50 pages due 2026-08-17, after which he will write a recommendation on no stated timeline, with the final call resting with the DEA Administrator. Broad adult-use Schedule III is now a multi-month administrative process with a litigation tail, not a dated catalyst. Price behaved accordingly — TLRY printed a fresh 52-week low of $4.20 on 2026-07-08 and has traded $4.35–4.38 since, below the 200-day, with TD Cowen cutting its target to $5 from $7 on 2026-07-14 while keeping a Buy. What remains is a $1.2B-annualized beverage-and-cannabis conglomerate with one genuinely growing leg (international medical) reporting Q4/FY2026 after the close on 2026-07-28 against a consensus of roughly -$0.01. That is an earnings print, not a reform trade, and the calendar is inside the window where fresh positioning is a coin flip.\n\n## Bull Case\n- International cannabis is the only accelerating leg and it is accelerating hard: Q3 FY2026 (reported ~2026-04-01) showed international cannabis +70% YoY on German legalization volumes, inside record net revenue of $206.7M (+11%) and gross profit of $55M (+6%). (Q3 FY2026 release)\n- Geographic expansion continues without needing US reform: Tilray Medical launched its first medical cannabis product in Panama on 2026-07-09, extending the medical footprint into Latin America.\n- Management reaffirmed FY2026 adjusted EBITDA guidance of $62–72M at the Q3 print — a company generating positive adjusted EBITDA rather than a pure cash-burn LP.\n- BrewDog adds roughly $200M of annual net revenue and $6–8M of FY2027 adjusted EBITDA, lifting global consolidated net revenue to ~$1.2B annualized and giving the platform a non-cannabis cash contributor.\n- The hemp cleanup is still coming: the Continuing Appropriations Act signed 2025-11-12 recriminalizes most intoxicating hemp-derived THC effective ~2026-11-12, with the U.S. Hemp Roundtable estimating ~95% of current hemp-cannabinoid products swept out — removing the gray-market undercut on licensed product.\n- The 2026-04-23 DOJ Final Order already moved FDA-approved cannabis drugs and state-licensed medical marijuana to Schedule III, with the registration window closing 2026-06-22. The administration has demonstrated it will act, which keeps the broader outcome live rather than theoretical.\n- Sell-side has not capitulated: consensus target sits around $6.33 versus a $4.35 tape, and TD Cowen held its Buy through the target cut.\n\n## Bear Case\n- The hearing produced a briefing calendar, not a decision. Briefs are due 2026-08-17, the ALJ set no date for his recommendation, and the DEA Administrator holds the final pen — with the losing side's litigation option intact. The date that anchored the trade is spent.\n- Price made a new 52-week low on 2026-07-08 at $4.20, during the hearing itself. A market that will not bid a name while its bullish catalyst is being heard in open session is telling the operator what it thinks of the outcome.\n- Shares lost roughly 11% over the trailing month against a Medical-sector gain of ~4.3% and an S&P 500 gain of ~1.3% — underperformance into the catalyst, not accumulation.\n- TD Cowen's 2026-07-14 target cut to $5 from $7 is a 29% haircut on a maintained Buy. Estimates are being marked down toward the tape, not the tape toward estimates.\n- Reform beta is structurally diluted. With BrewDog folded in, cannabis is roughly 31% of consolidated revenue; a favorable Schedule III outcome moves less than a third of the P&L, while the beverage business carries its own margin problems.\n- The round trip from ~$5 to ~$23 and back to ~$4 leaves overhead supply stacked at every level a recovery would have to clear, and reliably converts each reform headline into a distribution event.\n- Q4/FY2026 lands 2026-07-28 after the close with consensus near -$0.01, a ~105% swing from the year-ago quarter. Dilution is ongoing — the Lyphe Group acquisition was funded with ~1.6M new shares in early June 2026 alongside a debt-for-equity retirement of $6M of 2027 converts.\n\n## Setup & Price Structure\nThe structure is broken and has been for months. TLRY trades ~$4.35–4.38 as of 2026-07-16, below the 200-day SMA, having set a new 52-week low at $4.20 on 2026-07-08 — the prior $4.50 shelf that the April hearing low defended is gone. There is no higher low, no base, and no reclaim attempt to lean on. Every technical requirement for a momentum entry is unmet: the name needs a daily close back above the ~$5.80–6.00 area to put the 200-day back in play, which is 33–38% away. Between here and there sits the consensus target of $6.33 and TD Cowen's freshly cut $5, both above spot, which is the ordinary condition for a value trap rather than evidence of upside. A long from these levels is a bet that a 52-week-low print eight trading days before an earnings release marks the bottom.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-17 (confirmed)** — Post-hearing briefs due in the DEA rescheduling proceeding, 50-page cap, closing arguments included. This is a filing deadline, not a ruling; the ALJ recommendation follows on no announced schedule.\n- **No dated decision point** exists between now and the ALJ recommendation. Any move on rescheduling headlines in this window is sentiment, not resolution.\n\n## Elapsed catalysts\n\n- **2026-07-28 (confirmed, after close)** — Q4 and full-year FY2026 results for the period ended 2026-05-31; conference call 4:30 PM ET. Consensus EPS ~-$0.01. Key lines: whether FY adjusted EBITDA lands inside the reaffirmed $62–72M band, international cannabis growth versus the +70% Q3 comp, and first hard BrewDog contribution detail. *(passed 12d ago)*\n- **2026-07-28 → 2026-07-29** — FY2027 guidance, the first framing of the ~$1.2B annualized consolidated revenue base and the $6–8M BrewDog adjusted-EBITDA contribution. *(passed 11d ago)*\n\n## What Would Change Our Mind\nA daily close above $5.00 that reclaims the TD Cowen target level would be the first structural evidence in months, and a sustained daily close above $6.00 would put the 200-day back in play and turn this from a falling knife into an actual setup. Fundamentally, a Q4 print on 2026-07-28 that holds international cannabis growth near the +70% Q3 pace while landing FY adjusted EBITDA at the top of the $62–72M band — and guides FY2027 above the ~$1.2B annualized run-rate — would argue the operating business is compounding independent of Washington. On the policy side, an ALJ recommendation explicitly endorsing broad adult-use Schedule III, arriving before the hemp recriminalization date of ~2026-11-12, would restore the reform leg that the 2026-07-15 adjournment removed. Absent any of those, the name is a pass and the correct behavior on weakness is to stand aside, not to accumulate.\n\n## Correlation Notes\n- Trades as high-beta expression of the US cannabis-reform complex alongside CGC, CRON, ACB and the MSOS basket; single-name work is largely wasted because reform headlines move the group in lockstep.\n- Peer read-through is negative on quality: Canopy's FY2026 print (2026-06-15) paired strong volume growth — Q4 international cannabis +68%, Canada medical +27% YoY, FY net revenue +6% to C$284.6M — with a -$0.06 EPS miss on $71.2M Q4 revenue. The sector grows revenue and still bleeds.\n- Roughly 31% cannabis revenue mix means TLRY now correlates meaningfully to craft-beverage volumes and European medical distribution, which mutes the reform-beta the group is bought for. On a genuine rescheduling headline, purer US-exposed names should outrun it.\n- German medical cannabis volumes are the one exposure uncorrelated to US federal policy, and the Panama launch (2026-07-09) extends that decoupling.\n- The ~2026-11-12 hemp recriminalization date is a shared sector catalyst affecting all licensed operators; H.R. 7024 deferring it to 2028 would be a group-wide negative.",
  "first_seen": "2026-04-23",
  "last_analyzed": "2026-07-19T11:49:11+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}